Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.9752W HIGH $5.50
Volume
273.98 K
Value Traded
3.60 M
Short % Float
8.25%
Days to Cover
7.1
-14.5%Week
-31.19%1 Month
-23.75%3 Month
-31.68%6 Month
-99%5 Year
-99.67%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
164.76 M
EPS (TTM)
-1.40
P/E Ratio
-
Ent. Value
-25.23 M
Total Shares
57.01 M
Float Shares
32.86 M
Insiders
42.36%
Institutions
57.90%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
WHWK Catalyst Timeline
Dated clinical, regulatory and corporate events for Whitehawk Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Whitehawk Therapeutics, Inc.
291Total events
13Upcoming
71Tier-1 (high impact)
2017 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Poster PresentationPresentation
E-Poster 950 on durable and treatment-agnostic MUC16 expression in ovarian cancer presented at IGCS 2026
ovarian cancersource ↗
▲RWE DataClinical Data
Real-world analyses show MUC16 expression remains high and stable after standard-of-care therapies in ovarian cancer
ovarian cancersource ↗
●Poster PresentationPresentation
Poster P2.241: Durable and Treatment-Agnostic PTK7 Expression in EGFR Wild-Type Lung Adenocarcinoma Supports Targeted ADC Development at WCLC 2026
EGFR wild-type non-small cell lung cancersource ↗
▲RWE DataClinical Data
Real-world analyses show PTK7 expression remains stable after standard-of-care therapies in EGFR wild-type NSCLC
EGFR wild-type non-small cell lung cancersource ↗
●Poster PresentationHWK-007Presentation
Poster P2.241 on durable and treatment-agnostic PTK7 expression in EGFR wild-type lung adenocarcinoma at WCLC 2026
EGFR wild-type non-small cell lung cancersource ↗
▲RWE DataHWK-007Clinical Data
Real-world analyses supporting PTK7 as a durable ADC target in pretreated EGFR wild-type NSCLC presented at WCLC 2026
EGFR wild-type non-small cell lung cancersource ↗
▲Partnership / LicenseCorporate
Akari Therapeutics enters strategic research collaboration with Whitehawk Therapeutics to evaluate PH1 payload with Whitehawk's TOP1i ADC platform
oncologysource ↗
●IND Enabling CompleteAKTX-101Preclinical
Akari initiates IND-enabling studies for AKTX-101
oncology (Trop2-expressing cancers)source ↗
▲Partnership / LicenseCorporate
Biocytogen and Whitehawk enter global collaboration for bispecific antibody ADC development
cancersource ↗
◆Trial InitiationHWK-206Trial
Phase 1 trial for HWK-206 planned to initiate in Q3 2026
small-cell lung cancer and neuroendocrine tumorssource ↗
◆Oral PresentationPresentation
Whitehawk Therapeutics to present at Jefferies 2026 Global Healthcare Conference
●Poster PresentationHWK-007Presentation
HWK-007 study design presented as Trials-in-Progress poster at ASCO 2026
non-squamous, EGFR wild-type non-small cell lung cancer; platinum-resistant ovarian cancer; endometrial cancersource ↗
●Oral PresentationPresentation
Real-world analysis on SEZ6 presented at ASCO 2026
small-cell lung cancer and other neuroendocrine tumorssource ↗
◆Poster PresentationPresentation
Real-world characterization of SEZ6 expression in solid tumors poster at ASCO 2026
small cell lung cancer and other neuroendocrine tumorssource ↗
◆Oral PresentationPresentation
Virtual fireside chat at TD Cowen 7th Annual Oncology Innovation Summit
▲Partnership / LicenseCorporate
Option agreement with Hangzhou DAC for CPT113 for up to five new ADC programs
●Enrollment UpdateHWK-007Trial
Phase 1 dose-escalation trial of HWK-007 currently enrolling
PTK7-directedsource ↗
●Enrollment UpdateHWK-016Trial
Phase 1 dose-escalation trial of HWK-016 currently enrolling
MUC16-directedsource ↗
▲First Patient DosedHWK-007Trial
Phase 1 dose-escalation trial for HWK-007 ongoing
non-squamous, EGFR wild-type non-small cell lung cancer; platinum-resistant ovarian cancer; endometrial cancersource ↗
▲First Patient DosedHWK-016Trial
Phase 1 dose-escalation trial for HWK-016 ongoing
advanced ovarian and endometrial cancerssource ↗
◆Oral PresentationPresentation
Whitehawk Therapeutics to participate in Jones Trading Post-AACR Fireside Chat Series
◆Poster PresentationHWK-007Presentation
Preclinical assessment of HWK-007, a next-generation, PTK7-targeting ADC with novel bioconjugation and linker–payload technology
cancersource ↗
◆Poster PresentationHWK-206Presentation
Preclinical assessment of HWK-206, a next-generation, biparatopic, SEZ6-targeting ADC with novel bioconjugation and linker–payload technology
cancersource ↗
◆Preclinical PoCHWK-007Preclinical
Comprehensive preclinical proof-of-concept for HWK-007 presented at AACR
cancersource ↗
◆Preclinical PoCHWK-206Preclinical
Comprehensive preclinical proof-of-concept for HWK-206 presented at AACR
cancersource ↗
●Poster PresentationHWK-007Presentation
Preclinical assessment of HWK-007 poster at AACR 2026
non-squamous, EGFR wild-type non-small cell lung cancer; platinum-resistant ovarian cancer; endometrial cancersource ↗
◆Oral PresentationHWK-016Presentation
Preclinical assessment of HWK-016, a next-generation, MUC16-targeting ADC with novel bioconjugation and linker–payload technology
cancersource ↗
●Poster PresentationHWK-206Presentation
Preclinical assessment of HWK-206 poster at AACR 2026
◆Preclinical PoCHWK-016Preclinical
Comprehensive preclinical proof-of-concept for HWK-016 presented at AACR
cancersource ↗
●Poster PresentationHWK-016Presentation
Poster: MUC16 in ovarian cancer: high, stable expression across histologic subtypes, disease stages, and platinum sensitivity status supports antibody-drug conjugate development
ovarian cancersource ↗
▲Preclinical PoCPreclinical
Preclinical proof-of-concept data presented at AACR 2026 for ADC portfolio
◆Oral PresentationPresentation
Preclinical data presentation across portfolio at upcoming medical congress in Spring 2026
▲Runway Guidance UpdateCorporate
Cash runway expected to fund operations into at least 2H 2026
Past FDA Catalysts and PDUFA Decisions
How WHWK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | HWK-206 | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 74%
Micro Cap(rank 486 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HWK-016 Small moleculeNCT07470853 | PROC | Phase 1 | RECRUITING | 265 | Feb 1, 2028 | ||||||
| HWK-007 Small moleculeNCT07444814 | Endometrial Cancer | Phase 1 | RECRUITING | 226 | Dec 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every WHWK program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| nab-sirolimus | solid tumors with TSC1 or TSC2 inactivating alterations | 2023-12-14 | 19 patients received 1 post baseline scan and were evaluable for efficacy; all 18 patients received 1 post baseline scan and were evaluable for efficacy.Read More | Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab -Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations Interim results from investigatorRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Dugan MargaretOfficer (Chief Medical Officer) | Grant/Award | 19,132 19,132 held | $3.92 | 05/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in WHWK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in WHWK for Q2 2026. | ||||
WHWK Institutional Ownership Trends
WHWK Short Interest
Shares sold short, counted twice a month.
8.25%
Short % of Float
of tradable shares sold short
2.7M
Shares Sold Short
-0.6% vs prior count
7.1 High
Days to Cover
trading days of normal volume to buy every short share back
382.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How WHWK ranks across every disease it competes in
Competitive Position is a premium feature
See how WHWK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialWHWK News
WHWKWhitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
Whitehawk Therapeutics presented analyses at the IGCS 2026, highlighting MUC16 as a durable target for antibody-drug conjugates (ADCs) in ovarian cancer. The studies showed that MUC16 expression remains stable after various standard-of-care treatments and is associated with poor overall survival in high-grade serous ovarian carcinoma. This supports the development of HWK-016, a next-generation MUC16-directed ADC currently in Phase 1 trials.
Read more →WHWKWhitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
Whitehawk Therapeutics presented analyses at the IASLC 2026 WCLC, highlighting PTK7 as a durable ADC target in EGFR wild-type NSCLC. The studies showed stable PTK7 expression following standard treatments, suggesting its viability for targeted therapy. The findings support the ongoing development of HWK-007, a PTK7-directed ADC currently in Phase 1 trials.
Read more →WHWKWhitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
Whitehawk Therapeutics has appointed Dr. Vijay Iyengar to its Board of Directors, effective September 9, 2026. Dr. Iyengar, with over two decades of oncology experience, previously held senior roles at Incyte and Novartis. His leadership is anticipated to support Whitehawk's growth and development of its antibody-drug conjugate (ADC) portfolio.
Read more →WHWKWhitehawk Therapeutics to Participate in Upcoming Investor Conferences
Whitehawk Therapeutics, a clinical-stage oncology company, announced its participation in several upcoming investor conferences, including the Cantor Global Healthcare Conference and the Wells Fargo Healthcare Conference. Key executives will engage in investor meetings and a fireside chat at the Morgan Stanley Global Healthcare Conference. The company aims to highlight its innovative antibody drug conjugate cancer treatments.
Read more →WHWK▲ +15.5%on this news
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Whitehawk Therapeutics reported its Q2 2026 financial results, highlighting ongoing Phase 1 trials for HWK-007 and HWK-016, with HWK-206 set to initiate in Q3 2026. The company has $190 million in cash, expected to fund operations into the second half of 2028. Recent collaborations and financing efforts position the company well for future growth in antibody drug conjugate (ADC) development.
Read more →WHWKAkari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
Akari Therapeutics has announced a strategic research collaboration with Whitehawk Therapeutics to evaluate the compatibility of Akari's PH1 spliceosome-modulating payload technology with Whitehawk's ADC platform. The collaboration aims to conduct preclinical studies that could lead to innovative cancer treatments. Both companies will jointly assess the data generated to guide future development opportunities.
Read more →WHWKBiocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
Biocytogen and Whitehawk Therapeutics have announced a global collaboration aimed at developing bispecific antibody antibody-drug conjugates (ADCs). This partnership is expected to leverage both companies' expertise in biopharmaceuticals. Further details on the specific goals and timelines of the collaboration have not been disclosed.
Read more →WHWKWhitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
Whitehawk Therapeutics presented a real-world analysis at ASCO 2026, highlighting SEZ6 as a significant target for small cell lung cancer (SCLC) and other neuroendocrine tumors. The analysis indicates that SEZ6 is highly expressed in these cancers, supporting the development of the SEZ6-directed ADC, HWK-206, with an IND submission expected in mid-2026. The findings suggest promising therapeutic implications for patients.
Read more →WHWKWhitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
Whitehawk Therapeutics, a clinical-stage oncology company, announced that its President and CEO, Dave Lennon, will present at the Jefferies 2026 Global Healthcare Conference on June 4. The presentation will focus on the company's innovative antibody drug conjugate (ADC) treatments. A live webcast of the event will be available for 30 days post-presentation.
Read more →WHWKWhitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
Whitehawk Therapeutics has entered an option agreement with Hangzhou DAC to develop up to five new antibody-drug conjugate (ADC) programs using the CPT113 linker-payload technology. This agreement aims to enhance their existing ADC pipeline, which includes ongoing Phase 1 trials for HWK-007 and HWK-016. The company plans to submit Investigational New Drug applications for these new programs within the next 12-24 months.
Read more →WHWKWhitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
Whitehawk Therapeutics will participate in the TD Cowen 7th Annual Oncology Innovation Summit on May 27, 2026. CEO Dave Lennon will engage in a virtual fireside chat, discussing advancements in antibody drug conjugate cancer treatments. The event will be accessible via a live webcast and available for replay for 30 days.
Read more →WHWK▼ -7.8%on this newsshared move
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
Whitehawk Therapeutics will participate in the 2026 Stifel Virtual Targeted Oncology Forum, with CEO Dave Lennon leading a fireside chat on May 19, 2026. The event will be accessible via a live webcast and available for replay for 30 days. Whitehawk focuses on developing advanced antibody drug conjugates to enhance cancer treatment.
Read more →WHWK▲ +25.8%on this newsshared move
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
Whitehawk Therapeutics announced a successful private placement equity financing, raising approximately $87.5 million. The financing involves the sale of common stock and pre-funded warrants, with a closing date anticipated on May 14, 2026. Funds will be allocated towards working capital and advancing the company's antibody drug conjugate pipeline, extending its cash runway into the second half of 2028. Participation from existing investors underscores their confidence in the company's oncology therapeutic development efforts.
Read more →WHWK▼ -5.1%on this news
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Whitehawk Therapeutics, Inc. reported its financial results for Q1 2026, highlighting ongoing Phase 1 trials for its ADC assets, HWK-007 and HWK-016. The company maintains a strong cash position of $123 million, which is expected to support operations into 2028. An IND submission for HWK-206 is on track for mid-2026, with initial data anticipated in 1H 2027. However, the company reported increased operating losses and acknowledged uncertainties related to clinical development risks.
Read more →WHWKWhitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
Whitehawk Therapeutics presented new preclinical data on its ADC portfolio at the AACR Annual Meeting 2026. The data highlighted significant tumor regressions at low doses and favorable tolerability across various cancer models. Ongoing Phase 1 trials for HWK-007 and HWK-016 are progressing, with an IND submission for HWK-206 expected in mid-2026.
Read more →WHWKWhitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
Whitehawk Therapeutics, Inc. will participate in the Jones Trading Post-AACR Fireside Chat Series on April 23, 2026. CEO Dave Lennon, PhD, will discuss the company's advancements in antibody drug conjugate cancer treatments. The event will be accessible via a live webcast and available for replay for 30 days.
Read more →About Whitehawk Therapeutics, Inc.
Headquarters2 HEADQUARTERS PLAZA, MORRISTOWN, NJ, 07960
BIOPHARMAWATCH ELITE PLUS
Trade the next WHWK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime